126 related articles for article (PubMed ID: 466616)
1. Report of a clinical trial of a Canadian preparation of antihemophilic factor.
Magnin AA; Johnson SE
Can Med Assoc J; 1979 Aug; 121(4):422-4, 427. PubMed ID: 466616
[TBL] [Abstract][Full Text] [Related]
2. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
Perret BA; Poorbeik M; Morell A
Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
[TBL] [Abstract][Full Text] [Related]
3. Lyophilized cryoprecipitate for children with hemophilia A.
Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of a new factor VIII concentrate in hemophilic children].
Carnelli V; Cultrera S; Simoni L; Pasqui G; Busso B; Bagnato L
Pediatr Med Chir; 1983; 5(3):49-55. PubMed ID: 6417627
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII concentrate for hemophilia: comparison of two heat-treated products.
Walker IR; Pai MK; Blair BA; Johnston MA; Birkett NJ; Ofosu FA; Naylor DH
CMAJ; 1987 Jan; 136(2):150-2. PubMed ID: 3098401
[TBL] [Abstract][Full Text] [Related]
6. Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.
Bennett B; Ratnoff OD
J Clin Invest; 1972 Oct; 51(10):2593-6. PubMed ID: 4626847
[TBL] [Abstract][Full Text] [Related]
7. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
8. [The dosage of antihemophilic globulin, or antihemophilic plasma as well as Cohn's fraction I in factor VIII deficiency].
Hrubisková K
Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(3):363-8. PubMed ID: 4195283
[No Abstract] [Full Text] [Related]
9. Measurement of antihemophilic factor activity in plasma.
Penner JA
J Lab Clin Med; 1966 Jun; 67(6):1025-35. PubMed ID: 5916134
[No Abstract] [Full Text] [Related]
10. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII half-life and clinical phenotype of severe hemophilia A.
van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
[TBL] [Abstract][Full Text] [Related]
12. [Substitutive treatment of hemopjolia A using a new factor VIII concentrate].
Allain JP; Steinbuch M; Meunier L; Muller JY; Soulier JP
Nouv Presse Med; 1976 Apr; 5(16):1047-50. PubMed ID: 1272773
[TBL] [Abstract][Full Text] [Related]
13. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
Sultan Y; White GC; Aronstam A; Bosser C; Brackmann HH; Brochier G; Gormsen J; Mariani G; Roberts HR; Scarabin Y
Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516
[TBL] [Abstract][Full Text] [Related]
14. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII.
Kantrowitz JL; Lee ML; McClure DA; Kingdon HS; Thomas WR
Clin Ther; 1987; 9(4):405-19. PubMed ID: 3111706
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
Weippert M; Anders O; Schmidt M; Roewer J
Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A.
Chuansumrit A; Isarangkura P; Chantanakajornfung A; Kuhathong K; Pintadit P; Jitpraphai C; Hathirat P; Nuchprayoon C
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S69-73. PubMed ID: 10730521
[TBL] [Abstract][Full Text] [Related]
17. [Antihemophilic cryoprecipitate from fresh plasma and its use in hemophilia A].
Brüster H; Glassner K; Riech PC
Dtsch Med Wochenschr; 1967 Oct; 92(41):1859-66. PubMed ID: 6057144
[No Abstract] [Full Text] [Related]
18. The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial.
Hershgold EJ; Pool JG; Pappenhagen AR
J Lab Clin Med; 1966 Jan; 67(1):23-32. PubMed ID: 5321736
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
20. [Concentrated antihemophilic globulin in the treatment of hemorrhagic syndromes].
Baklaja F; Cvetković V; Stajić M; Krivokapić L
Bilt Hematol Transfuz; 1976; 4(3):61-6. PubMed ID: 1008799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
